Rishi Puri

Mr. Rishi Puri

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RGRui Guo
Rui Guo
YSYizhe Sun
Yizhe Sun
MLMatthew Y. Lim
Matthew Y. Lim
HSHardik Shah
Hardik Shah
Joao A PauloJoao A Paulo
Joao A Paulo
BGBenjamin Gewurz`
Benjamin Gewurz`
B lymphocytes play major adaptive immune roles, producing antibodies and driving T cell responses. However, how immunometabolism networks support B cell activation and differentiation in response to distinct receptor stimuli remains incompletely understood. To gain insights, we systematically investigated acute primary human B cell transcriptional, translational, and metabolomic responses to B cell receptor (BCR), TLR9, CD40-ligand (CD40L), IL-4, or combinations thereof. T cell–independent BCR/TLR9 costimulation, which drives malignant and autoimmune B cell states, highly induced transaminase branched chain amino acid transaminase 1 (BCAT1), which localized to lysosomal membranes to support branched chain amino acid synthesis and mTORC1 activation. BCAT1 inhibition blunted BCR/TLR9, but not CD40L/IL-4–triggered B cell proliferation, IL-10 expression, and BCR/TLR pathway–driven lymphoma xenograft outgrowth. These results provide a valuable resource, reveal receptor-mediated immunometabolism remodeling to support key B cell phenotypes, and identify BCAT1 as an activated B cell therapeutic target.

21 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
Diffuse large B-cell lymphomas (DLBCL) are genetically and phenotypically heterogeneous, making diagnosis and treatment challenging. Current models suggest DLBCL derive from follicular B cells engaged in adaptive immune responses. By studying co-occurring truncating mutations in SPEN and NOTCH2 in the BN2-DLBCL subtype, our data suggest a previously unrecognized extra-follicular trajectory. Using animal models and human specimens, we find this cooperative mutational axis supports expansion of putative clonal precursors with features of marginal zone, memory and a distinct, autoimmune B-cell-like state. This trajectory is associated with sex-biased outcomes: female patients and mice exhibit reduced survival compared to males in our cohorts. Further analysis links this disparity to enhanced X-chromosome-linked expression and functionality of toll-like receptor signaling. We show that IRAK inhibition represents a potential sex-specific therapeutic strategy in preclinical models. These findings support a distinct developmental origin for BN2-DLBCL and identify a high-risk female population with actionable targets for precision therapy.

3 August 2026
Verified
Other
Open access
PDF file
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.

12 August 2026
Verified
Other
Open access
PDF file
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
Lymphomas with combined SpenLOF and Notch2GOF mutations exhibit an AiBC-like phenotype, which is attenuated in males.

12 August 2026
Verified
Other
Open access
PDF file
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
Combined SpenLOF and Notch2GOF mutant lymphomas show signs of XChr dysregulation and TLR pathway dependencies.

12 August 2026
Verified
Other
Open access
PDF file
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.